论文部分内容阅读
[目的]探讨紫杉醇脂质体在妇科恶性肿瘤治疗中的有效性和安全性。[方法]2005年1月～2008年5月以紫杉醇脂质体联合顺铂或卡铂治疗妇科恶性肿瘤患者31例,其中卵巢癌20例、宫颈癌10例及子宫内膜癌1例,分析紫杉醇脂质体的安全性、有效性和毒副反应。[结果]卵巢癌患者中,CR8例,PR5例,SD2例,PD3例,总有效率为71%;骨髓抑制发生率19%。宫颈癌患者术前经化疗肿瘤明显缩小。[结论]紫杉醇脂质体联合顺铂或卡铂对卵巢癌及宫颈癌具有较好的疗效,安全性较好,毒副反应少。且应用紫杉醇脂质体前不需大剂量激素预处理。
[Objective] To investigate the efficacy and safety of paclitaxel liposomes in the treatment of gynecological malignancies. [Method] From January 2005 to May 2008, 31 cases of gynecological malignant tumor were treated with paclitaxel liposome combined with cisplatin or carboplatin, including 20 cases of ovarian cancer, 10 cases of cervical cancer and 1 case of endometrial carcinoma. Paclitaxel liposomes are safe, effective and toxic side effects. [Results] Of the patients with ovarian cancer, CR8, PR5, SD2 and PD3 had a total effective rate of 71% and bone marrow suppression rate of 19%. Cervical cancer patients preoperative chemotherapy tumor was significantly reduced. [Conclusion] Paclitaxel liposome combined with cisplatin or carboplatin has good curative effect on ovarian cancer and cervical cancer, and has good safety and few toxic and side effects. And the application of paclitaxel liposomes without large doses of hormone pretreatment.